Annual Meeting of the Hematology Branch, CPAM | Professor Yajing Xu: Long-Term Follow-Up Management After Hematopoietic Stem Cell Transplantation—From Digital Solutions to Primary Care Collaboration

Annual Meeting of the Hematology Branch, CPAM | Professor Yajing Xu: Long-Term Follow-Up Management After Hematopoietic Stem Cell Transplantation—From Digital Solutions to Primary Care Collaboration

From April 10 to 11, 2026, the Annual Academic Meeting of the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care (CPAM), together with the “Huatuo Project” MDT Symposium, was held in Changsha. During the meeting, Professor Yajing Xu, Executive Chair and Director of Hematology at Xiangya Hospital, Central South University, was invited by Hematology Frontier to share her insights on the clinical challenges of long-term follow-up after hematopoietic stem cell transplantation (HSCT), standardized management models, and pathways for primary care collaboration. Her discussion aimed to promote the standardization of follow-up systems and improve long-term survival and quality of life for patients.
AACR China Voice | Qilu Pharmaceutical Showcases Multiple Innovative Breakthroughs at AACR, Driving Global Advances in Oncology Through Originative Innovation

AACR China Voice | Qilu Pharmaceutical Showcases Multiple Innovative Breakthroughs at AACR, Driving Global Advances in Oncology Through Originative Innovation

From April 17 to 22, 2026, the Annual Meeting of the American Association for Cancer Research—one of the most influential events in global oncology—was held. At this premier scientific forum, the R&D team of Qilu Pharmaceutical presented a series of independently developed innovative research achievements spanning cutting-edge fields such as antibody–drug conjugates (ADCs), bispecific and trispecific antibodies, and small-molecule therapies.
AACR China Voice | Professor Tao Zhu: First-in-Human Study of CLDN6 ADC QLS5132 Demonstrates Promising Efficacy and Safety, Opening New Directions for Platinum-Resistant Ovarian Cancer

AACR China Voice | Professor Tao Zhu: First-in-Human Study of CLDN6 ADC QLS5132 Demonstrates Promising Efficacy and Safety, Opening New Directions for Platinum-Resistant Ovarian Cancer

Platinum-resistant recurrent ovarian cancer (PROC) remains a major clinical challenge, characterized by poor overall prognosis, limited effective treatment options, high unmet medical need, and suboptimal safety profiles. Innovative treatment strategies are urgently needed.
Professor Rong Fu: From Data to Mechanism—A Comprehensive Interpretation of Thrombosis in PNH and Emerging Strategies for Prevention and Management

Professor Rong Fu: From Data to Mechanism—A Comprehensive Interpretation of Thrombosis in PNH and Emerging Strategies for Prevention and Management

From March 27 to 28, 2026, the 9th Beijing Conference on Thrombosis and Hemostasis and the 7th Beijing Summit Forum on Hematologic Malignancies and Immunology was held in Beijing, bringing together leading experts from China and abroad to discuss advances in thrombosis, hemostasis, hematologic malignancies, and immunology.
North–South Summit 2026 | Professor Leiping Wang: HER2-Positive Metastatic Breast Cancer—Has the First-Line ADC Era Truly Arrived?

North–South Summit 2026 | Professor Leiping Wang: HER2-Positive Metastatic Breast Cancer—Has the First-Line ADC Era Truly Arrived?

With the release of data from studies such as DESTINY-Breast09 (DB-09), antibody–drug conjugates (ADCs) are gaining increasing prominence in the first-line treatment of HER2-positive metastatic breast cancer (MBC). However, while the traditional THP regimen (trastuzumab + pertuzumab + taxane) remains firmly established as the guideline-preferred standard, the question remains: has the “era of ADC dominance” truly begun? During the “Deep Dive” session at the 8th North–South Breast Cancer Forum, Professor Leiping Wang from Fudan University Shanghai Cancer Center addressed this question. She emphasized that although ADCs have opened the door to first-line therapy with impressive progression-free survival (PFS) benefits, their full integration into clinical practice still requires further validation, particularly in the context of refined disease management and treatment sequencing.
Breaking News: Academician Binghe Xu Leads PHILA Study Published in The BMJ—A “China Solution” for First-Line Dual Targeting in HER2-Positive Metastatic Breast Cancer

Breaking News: Academician Binghe Xu Leads PHILA Study Published in The BMJ—A “China Solution” for First-Line Dual Targeting in HER2-Positive Metastatic Breast Cancer

On March 16, 2026, the long-term follow-up results of the randomized, double-blind, multicenter Phase III PHILA study were published online in The BMJ. The corresponding author is Academician Binghe Xu from the Cancer Hospital, Chinese Academy of Medical Sciences, with Professor Fei Ma (Cancer Hospital, Chinese Academy of Medical Sciences) and Professor Min Yan (Henan Cancer Hospital) as co–first authors. With a median follow-up of 45.5 months, the study demonstrated that first-line treatment with pyrotinib in combination with trastuzumab and docetaxel significantly improved overall survival (OS) in patients with HER2-positive metastatic breast cancer, reducing the risk of death by 26%. These findings establish a dual-targeted regimen that reflects a distinct “China-developed strategy” for first-line treatment in this population.